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There is strong evidence indicating that alopecia areata
is a tissue-speci¢c, autoimmune disease. Hair loss is
associated with a perifollicular lymphocytic in¢ltrate
made up primarily of CD4þ cells, along with a
CD8þ intrafollicular in¢ltrate. Evidence of immune
activation includes expression of HLA-DR; HLA-
A,B,C; and ICAM-1 on the follicular epithelium. It is
likely that the follicular expression of HLA-DR and
ICAM-1 is induced by interferon-c produced by Tcells.
Antibodies to follicular epithelium are often present,
but their signi¢cance is not known. Lesional scalp from
alopecia areata patients grafted onto nude mice regrows
hair coincident with a loss of in¢ltrating lymphocytes
from the graft. Hair loss can be transferred to human
scalp explants on SCID mice by injection of lesional T
cells. It is necessary to activate theTcells by culture with
follicular autoantigens. Melanocyte-associated antigens
are also capable of activating T cells to induce hair loss,
suggesting that they are capable of functioning as auto-
antigens for alopecia areata. Parallel evidence in rodent
models of spontaneous alopecia areata also strongly sup-
ports a role for T cells in the pathogenesis of this condi-
tion.Keywords: human/skin/autoimmunity/SCID/T lymphocites.
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T
here is much suggestive evidence that alopecia areata
(AA) is a tissue-speci¢c, autoimmune disease. AA re-
sponds to immunosuppressive doses of systemic ster-
oids (Kiesch et al, 1997) as well as to immunotherapy
with contact sensitizers (Micali et al, 1996). The con-
dition also has an association with additional autoimmune pro-
cesses such as autoimmune thyroiditis (Milgraum et al, 1987) and
vitiligo (Shellow et al, 1992). Furthermore, AA has a genetic asso-
ciation with HLA immunoregulatory genes (reviewed below).
Lesional scalp from AA patients grafted onto nude mice regrows
hair coincident with a loss of in¢ltrating lymphocytes from the
graft (Gilhar and Krueger, 1987).
GENETIC LINKAGE STUDIES OFALOPECIA AREATA
Many autoimmune diseases have linkage associations with HLA
antigens.The function of HLA molecules is to present antigens to
T lymphocytes in the form of peptides. This complex is then re-
cognized by the T cell receptor. Not all HLA molecules bind all
peptides, and there are distinct amino acid^binding motifs that
determine which peptides are bound by each HLA molecule
(Sette et al, 1989; Hunt et al, 1992; Rudensky et al, 1992; Rammen-
see et al, 1993). This forms much of the basis for the genetic con-
trol of immune reactivity, as well as part of the genetic tendency
for speci¢c autoimmune diseases.
AA has HLA associations with DQB103 (Welsh et al, 1994;
Morling et al, 1991) and HLA-B18 (Hacham-Zadeh et al, 1981),
and possibly HLA-A2 (Hordinsky et al, 1984). The LOD score for
HLA-DR is 2.34 and that for DQB1 is 2.41, with a signi¢cant
association with DQB1302 (de Andrade et al, 1999). These asso-
ciations with HLA-DR and HLA-DQ suggest a role for CD4þ
T cells in AA. However, associations with HLA-A,B,C were not
examined in these most recent studies. Because HLA-DR,DP,DQ
molecules present antigen to CD4þ T cells, and HLA-A,B,C
molecules present antigen to CD8þ T cells, the recent data on
CD8þ T cells in transferring AA (reviewed below) suggest that
genetic linkage studies should be expanded to examine the role
of HLA-A,B,C molecules.
There is genetic evidence suggesting a di¡erence between alo-
pecia totalis/universalis (AT/AU) and patchy AA. Long-standing
AT/AU has an association with DQB10301 (Colombe et al,
1995; Colombe et al, 1999) that is not found for long-standing pat-
chyAA. However, both patient groups had a positive association
with HLA-DQ3 (DQB103). These associations are important, as
they suggests di¡erence in molecular pathogenesis for these AA
variants (Price and Colombe, 1996).
Autoimmune diseases result from many factors, including
the interaction of the genetic background of the immune system
with the environment. It is probable that AA and other autoim-
mune diseases are polygenic, with multiple potential routes of
genetic susceptibility. In addition to HLA genes, there is known
genetic polymorphism in cytokine receptors and antigen-proces-
sing molecules. Given the role of environment in induction of
immune-mediated disease, genetics alone is unlikely to supply a
complete explanation of disease development.
AUTOANTIBODIES TO HAIR FOLLICLES AND
ALOPECIA AREATA
Circulating autoantibodies to follicular structures are reproduci-
bly reported in biopsies of AA (Tobin et al, 1997a). These anti-
bodies are also reported in normal controls, and there is no
consistent pattern of reactivity of antibodies to hair follicle struc-
tures. Antibodies to hair follicles are also found in C3H/HeJ mice
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(Tobin et al, 1997b) and DEBR rats (McElwee et al, 1996a) with
AA. However, there is no evidence that these antibodies are
pathogenic in either humans or animal models. It is not possible
to transfer AA by injection of patient IgG into human skin ex-
plants on nude mice (Gilhar et al, 1992). Furthermore, AA has
been reported in a child with common variable immunode¢-
ciency (Kilic et al, 1999). Although it has not been possible to
assign a pathogenic role to autoantibodies in AA, they are a con-
sistent ¢nding in both human, and rodent disease. It is possible
that autoantibodies to follicular structures are a marker for
CD4þ Tcell recognition of hair follicles.
IMMUNOHISTOCHEMISTRY SUGGESTS A ROLE FOR
IMMUNE ACTIVATION IN ALOPECIA AREATA
The histology of AA suggests a role for lymphocytes in the in-
duction of hair loss. Hair loss is associated with a perifollicular
lymphocytic in¢ltrate made up primarily of CD4þ cells along
with a CD8þ intrafollicular in¢ltrate (Todes-Taylor et al, 1984).
Evidence for immune activation includes expression of both
HLA-DR and ICAM-1 on the follicular epithelium (Messenger
et al, 1985; Khoury et al, 1988; Mcdonagh et al, 1993). Interferon-g
(INF-g is capable of inducing hair follicle expression of both
HLA-DR and ICAM-1. In addition, there is aberrant expression
of HLA-A,B,C on the follicular epithelium of the hair bulb
(Brocker et al, 1987). Normal hair bulb epithelium is unusual in
that it lacks expression in HLA-A,B,C and may represent an im-
mune privileged site. It has been proposed that the induction of
HLA-A,B,C as well as HLA-DR promotes T cell recognition of
follicular autoantigens. Microvascular endothelial cells express the
adhesion molecules ICAM-1 and ELAM-1 (Ghersetich et al,
1996). These adhesion molecules are signi¢cant because they are
critical in the homing of lymphocytes to sites of in£ammation.
At the ultrastructure level, AA is marked by degeneration of pre-
cortical keratinocytes and melanocytes of the hair bulb, suggest-
ing that these are targets of immune attack (Tobin, 1997c). The
above ¢ndings are suggestive of a T lymphocyte^mediated in-
£ammatory response that may be directed toward antigens pre-
sented by HLA-DR or HLA-A,B,C.
ANIMAL MODELS OF SPONTANEOUS ALOPECIA
AREATA
C3H/HeJ mice develop spontaneous hair loss with aging, which
demonstrates many features of AA, including in£ammatory in¢l-
trate of lymphocytes and response to intralesional steroid
injection (Sundberg et al, 1994). Alopecia can be transmitted to
normal C3H/HeJ mice by grafts of involved skin (McElwee
et al, 1998). Grafting to immunode¢cient C3H/SmnC Prkd
(scid)/J mice does not result in hair loss, however, suggesting in-
volvement of the host immune system. In common with human
AA, hair follicle epithelium expresses aberrant levels of MHC
class I, MHC class II, and ICAM-1 (Freyschmidt-Paul et al, 1999).
The condition shares with human disease the ability to respond
to topical immunotherapy. The DEBR rat is a second, similar,
model of spontaneous AA (Michie et al, 1991). As with the C3H/
HeJ mouse model, it responds to cyclosporine A with reduction
of lymphocytic in¢ltrate and hair regrowth (Oliver and Lowe,
1995). Both of these models have been used to study the involve-
ment of T cells in the pathogenesis of AA.
EVIDENCE THATALOPECIA AREATA IS MEDIATED
BY T LYMPHOCYTES
We have shown that it is possible to transfer AA to human scalp
explants on SCID mice by the injection of scalp-in¢ltrating T
lymphocytes (Gilhar et al, 1998). It was necessary to ¢rst activate
the T lymphocytes in vitro by culture with hair follicle homoge-
nate in the presence of antigen-presenting cells. Culture with
nonfollicular scalp homogenate did not induce hair loss (Gilhar
et al, 1999). This suggests that AA is transferred byT lymphocytes,
which recognize a hair follicle antigen. Transfer of hair loss in the
human scalp explant/SCID mouse system requires cooperation
between CD8þ T cells and CD4þ T cells (Gilhar et al, 2002).
That depletion of either CD8þ Tcells (McElwee et al, 1996b) or
CD4þ T cells (McElwee et al, 1999) can reverse AA in the
DEBR rat also supports a synergy or cooperation between the
two.
In£ammatory T cells in AA are cytotoxic and possess both
the Fas/Fas Ligand and the granzyme B cytotoxic mechanisms
(Bodemer et al, 2000). T cells cloned from lesional scalp also pro-
duce cytokines that inhibit keratinocyte proliferation (Thein et al,
1997), which may provide an additional mechanism for interfer-
ence with the anagen phase of the hair cycle. It is proposed that
the CD4þ T cells provide help for the e¡ector function of the
CD8þ T cells. A role for CD8þ T cells in AA is supported by
the ability of patients with AIDS and de¢cient CD4þ T cell
function to develop AA (Cho et al, 1995).
T cell cytokines such as INF-g appear to have a critical role in
the pathogenesis of AA. Injection of INF-g into human scalp ex-
plants on nude mice induces expression of ICAM-1 as well as
HLA-DR (Gilhar et al, 1993), and it induces HLA-DRon cultured
dermal papilla cells (Konig et al, 1997). INF-g has similar e¡ects
on cultured human keratinocytes. In situ expression of in£amma-
tory T cell cytokines, including INF-g, IL-2, and TNF-a, has
been demonstrated in lesional skin of AA patients, indicating a
TH1 cytokine pro¢le (Ho¡mann et al, 1994). INF-g also has the
ability to induce HLA-A,B,C expression, which may have an im-
portant role in abrogating immune privilege in the hair follicle.
POSSIBLE LINK BETWEEN ALOPECIA AREATA AND
PIGMENT-RELATEDAUTOANTIGENS
It has been hypothesized that the autoantigen(s) of AA is mela-
nocyte associated (Paus et al, 1994). The initial basis for this is the
frequent clinical observation that with disease activity pigmented
hairs are lost preferentially to nonpigmented (e.g., white) hairs.
With regrowth, moreover, there is a tendency for the initial re-
growing hairs to be white. Melanocytes are a signi¢cant compo-
nent of the hair bulb, which is the site of immunological attack.
Furthermore, there is an association of AA with vitiligo (Shong
and Kim, 1991; Shellow et al, 1992), and hair bulb melanocytes in
AA show both histological and ultrastructural abnormalities
(Tobin et al, 1990).
Antibodies against hair follicle melanocytes were found asso-
ciated with alopecia totalis (AT) in patients with autoimmune
polyendocrine syndrome type I (Hedstrand et al, 1999). Some of
these patients also had vitiligo. It is possible to induce lympho-
cyte-mediated alopecia in mice immunized against melanocyte-
associated (e.g., melanoma) antigens (Becker et al, 1996).
Melanocytes from hair follicle and epidermis have di¡erent
phenotypes and antigenic properties in culture, and it is postu-
lated they represent distinct populations (Tobin and Bystryn,
1996). If true, this could explain preferential targeting of epider-
mal melanocytes in vitiligo and hair follicle melanocytes in AA.
Paus and colleagues have hypothesized that induction of class I
MHC (HLA-A,B,C) in AA allows an autoaggressive response by
melanocyte-reactive CD8þ T cells (Paus et al, 1994). They sug-
gested that the CD8þ cells induce HLA-DR on the a¡ected
hair follicles by production of INF-g, resulting in a second wave
of helper CD4þ cells. We previously reported the presence of
CD4þ autoreactive T cells in the in¢ltrate of AA (Kalish et al,
1992). This is also supported by our ¢ndings of CD4þ and
CD8þ involvement in the transfer of AA in the human scalp
explant/SCID mouse system.
Using the SCID mouse transfer system, we demonstrated that
melanocyte-associated peptides are capable of activating lesional
T cells to induce hair loss (Gilhar et al, 2001). Scalp T cells from
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lesional (bald) AA scalp were cultured with antigen-presenting
cells and antigen, along with IL-2. They were then injected into
autologous lesional scalp grafts on SCID mice and hair regrowth
was measured. Hair follicle homogenate was used as an autoanti-
gen control.Tcells cultured with melanoma homogenate induced
statistically signi¢cant reduction in hair growth (po0.01 by ANO-
VA). HLA-A2-restricted melanocyte peptide epitopes were then
tested with lesional scalp T cells from HLA-A2-positive AA pa-
tients. Melanocyte peptide^activated T cells signi¢cantly reduced
the number of hairs regrowing in two experiments with six pa-
tients (po0.001 by ANOVA). Injected scalp grafts showed histologic
and immunochemical changes of AA. The most consistent
peptide autoantigens were the Gp100-derived G9-209 and G9-
280 peptides, as well as MART-1 (27^35). Melanocyte peptide
epitopes can function as autoantigens for AA. Multiple peptides
were recognized, suggesting epitope spreading.
POTENTIAL APPLICATIONS TO TREATMENT OF
ALOPECIA AREATA
AA appears to be a TH1 autoimmune condition meditated by
both CD4þ and CD8þ T cells, with a central role for INF-g.
Neuropeptides, such as calcitonin gene^related peptide (CGRP),
may have a role in induction of the condition. Melanocyte-asso-
ciated peptides are capable of functioning as autoantigens, but the
full range of autoantigens is not known. Potential targets for
therapy include interference with CD4þ or CD8þ T cell anti-
gen recognition, e¡ector function, cytokine pro¢les, antigen pre-
sentation, homing, and costimulation. With characterization of
the autoantigen pro¢le, it may be possible to develop a hyposen-
sitization or immune deviation protocol.
There are multiple immunomodulatory agents under develop-
ment that have potential application to AA. AA appears to be
mediated by a TH1 response with production of INF-g (Ho¡-
mann et al, 1994). Psoriasis has similarities to AA in that it also
involves a TH1 T cell response. IL-10 inhibits TH1 responses and
promotes TH2 responses (Schwarz et al, 1994). It was found e¡ec-
tive against psoriasis in a phase II trial (Asadullah et al, 1998). Suc-
cessful immunotherapy of AA is marked by a decrease in INF-g
production and an increase in IL-10 (Ho¡mann et al, 1994). On
this basis, a trial of intralesional IL-10 for AAwould be rational.
CTLA4-Ig is a recombinant fusion molecule that blocks CD28-
mediated costimulation of T cells (Schwartz, 1992). It has also
shown e⁄cacy against psoriasis in phase I trials (Abrams et al,
1999). Humanized monoclonal antibodies have been produced
that are directed at molecules required for T cell function. Mono-
clonal antibodies with activity against psoriasis in phase I or II
studies include anti-CD11a (LFA-1) (Gottlieb et al, 2000) and
anti-CD4 (Isaacs et al, 1997). All of the above immunomodulatory
agents have potential for treatment of AA. On the basis of our
SCID mouse transfer data, anti-CD8 is predicted to also have ac-
tivity against this disease. Basic research has provided a rational
basis for selection of novel agents with potential activity against
AA. Clinical investigators now have the considerable challenge of
testing these possibilities.
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